Is 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide? Is 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide safe for nursing mother and child? Does 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide extracts into breast milk? Does 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide has any long term or short term side effects on infants? Can 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide influence milk supply or can 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide decrease milk supply in lactating mothers?

4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide was removed from sale in the United States by the U.S. Food and Drug Administration because of long-term cardiovascular toxicity. Limited information indicates that levels of 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide in breastmilk are low. Because there is little published experience with 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide safety during breastfeeding, other agents may be preferred, especially while nursing a newborn or preterm infant.

A single 40 mg dose of parecoxib, a prodrug of 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide, was given intravenously to 40 mothers at an average of 41.9 hours after delivery. The neonatal adaptive score of the breastfed infants was normal at an average of 21.8 hours after the dose.[2]

A study compared 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide 20 mg and placebo for their opiate-sparing activity in post-cesarean section pain. All patients received epidural fentanyl and bupivacaine as well as intraspinal morphine for postoperative pain. No difference was observed in breastfeeding success rate between mothers who received 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide (n = 25) and placebo (n = 23).[2]